论文部分内容阅读
目的:观察缬沙坦联合丹参注射液治疗乙型肝炎肝硬化的临床疗效。方法:将50例患者随机分为治疗组27例,对照组23例,2组在相同治疗基础上,治疗组加用血管紧张素Ⅱ受体拮抗剂缬沙坦80mg/天,2月为1疗程。观察2组肝功能指标、肝纤维化指标、血液流变学指标及不良反应。结果:治疗后治疗组肝功能各指标与治疗前比较,差异均有非常显著性意义(P<0.01),与对照组治疗后比较,差异有显著性意义(P<0.05)。治疗后治疗组肝纤维化各指标与治疗前比较,差异均有非常显著性意义(P<0.01),与对照组治疗后比较,差异有显著性意义(P<0.05)。治疗后治疗组血液流变学各指标与治疗前比较,差异均有非常显著性意义(P<0.01),与对照组治疗后比较,差异均有显著性意义(P<0.05)。对照组全血黏度、全血还原黏度与治疗前比较,差异有显著性意义(P<0.05)。结论:缬沙坦联合丹参注射液是治疗乙型肝炎肝硬化的有效方法之一。
Objective: To observe the clinical efficacy of valsartan combined with danshen injection in the treatment of hepatitis B cirrhosis. Methods: Fifty patients were randomly divided into treatment group (n = 27) and control group (n = 23). The two groups were treated with valsartan 80 mg / day as the angiotensin Ⅱ receptor antagonist Course of treatment. Two groups of liver function indexes, liver fibrosis indexes, hemorheology indexes and adverse reactions were observed. Results: After treatment, the indexes of liver function in treatment group were significantly different from those before treatment (P <0.01), and there was significant difference between the two groups after treatment (P <0.05). After treatment, the indexes of liver fibrosis in the treatment group were significantly different from those before treatment (P <0.01), and there was significant difference between the treatment group and the control group after treatment (P <0.05). After treatment, the indexes of hemorrheology in the treatment group were significantly different from those before treatment (P <0.01), and the difference was significant (P <0.05) compared with the control group after treatment. The control group of whole blood viscosity, whole blood reduction viscosity compared with before treatment, the difference was significant (P <0.05). Conclusion: Valsartan combined with Salvia injection is one of the effective methods for the treatment of hepatitis B cirrhosis.